Fitzpatrick I-VI: Why Skin-Type Diversity Rules Out a Single-Country Australia Strategy

If your US or EU label needs the full phototype range, no Australian cohort can supply it alone. That is a study-design constraint, not a quality judgment.

September 7, 2026

7

min read

By

Julio G. Martinez-Clark, CEO, bioaccess®

Australia

Latin America

First-in-Human

Study Design

Panama

Medical Devices

What does Australia do well here?

Concede the strengths first, because they are real and because ignoring them would make this argument easy to dismiss. Australia has strong dermatology and clinical-research infrastructure, capable investigators, disciplined documentation, and a deep clinical literature in skin disease. If you need rigorous dermatologic assessment, Australian sites deliver it.

So be precise about what this article claims. The gap is population phototype representation — not capability, not quality, not investigator skill. No site, however good, can enroll participants who do not live in its catchment. This is a demographic constraint on study design, and it is one of the few country-selection factors that cannot be fixed by choosing a better site.

What is the Fitzpatrick scale, and why does it matter?

The Fitzpatrick scale classifies skin by phototype across six categories, I through VI, running from lighter to darker pigmentation. It is the shared vocabulary regulators, reviewers, and clinicians use to describe whether a study cohort actually resembles the population a product will meet on the market.

Two facts set up the whole problem. First, Australia's population is predominantly Fitzpatrick phototypes I-III. Second, US and EU product launches increasingly require representation across the full Fitzpatrick I-VI range. Those two facts do not overlap, and where they fail to overlap is where programs discover a gap late.

The frame: this is a design problem you solve at protocol time, not a data problem you fix at submission time.

Which devices are exposed to phototype variation?

Full-range representation matters most where pigmentation can plausibly change how a product performs or how safely it performs. In practice that means:

• Dermatology products, where the condition, its presentation, and the endpoint assessment all interact with skin type.
• Aesthetics products, where the treated tissue is the skin itself and the acceptable dose window can differ by phototype.
• Optical technologies, where light absorption and scattering depend on pigmentation.
• Energy-based technologies, where energy deposition in pigmented tissue is part of the mechanism.
• Imaging technologies, where signal acquisition and image quality can vary with skin pigmentation.

If your device sits in any of those categories, a reviewer's obvious question is whether performance and safety hold across the range — and a cohort drawn overwhelmingly from phototypes I-III cannot answer it. Not because the data are poor, but because the range was never in the study.

Where does a single-country Australia strategy fall short?

A single-country Australia strategy structurally under-represents phototypes IV-VI. "Structurally" is the operative word: this is a property of the available catchment, so it survives every mitigation you might attempt inside Australia. Adding sites does not fix it. Recruiting harder does not fix it. Extending the enrollment window does not fix it.

Notice what the middle row actually costs. A late second country is not a small amendment. It is another regulatory submission, another ethics cycle, another set of contracts and import permits, another activation timeline, and a data package that has to be harmonized across arms that were never designed together.

How does a multi-arm Latin America design solve it?

A multi-arm Latin America design — for example Panama plus Brazil plus the Dominican Republic — delivers the full Fitzpatrick I-VI range within one protocol, because those populations span the spectrum. The diversity is not engineered through unusual recruitment tactics; it is a property of who lives there.

That structure gives you three things at once. One protocol and one statistical plan, so the arms are designed to be pooled rather than reconciled afterward. Multiple recruiting fronts, which shortens the interval from activation to a closed cohort. And the dense catchments described in the Australian catchment math, which keep the screening funnel moving in each arm.

Why design the multi-arm study up front?

Because the alternative is discovering the constraint after you have spent the money. Ask one question before you pick a country: does my US or EU submission or label need evidence across the full Fitzpatrick range? If the honest answer is yes, or even probably, then a single-country cohort that cannot supply that range is not a cheaper option — it is a partial study you will pay to complete later.

Designing the multi-arm study up front costs a little more planning and considerably less rework. The arms share a protocol, the endpoints are defined once, phototype representation is a stated enrollment target rather than a post-hoc observation, and the dataset arrives whole.

For the full head-to-head across cost, catchment, diversity, travel, and entity requirements, start with the pillar: Australia vs. Latin America for first-in-human medical device trials. For the wider option set, see alternatives to Australia for first-in-human trials in 2026.

Frequently asked questions

What is the fastest next step?

Send us your protocol synopsis, your cohort size, and your phototype representation requirement, and we will map the arms that deliver it and the timeline to first-patient-in. Get a first-in-human feasibility read in 72 hours.

Get your feasibility read

See our Panama program